Lesional therapies for in-transit melanoma.
Ashlie NadlerNicole J Look HongNasrin AlaviWadid AbadirFrances C WrightPublished in: Journal of surgical oncology (2020)
IL-2 may be considered for the treatment of ITM with multiple or rapidly developing lesions where there would otherwise be significant morbidity with surgery, given pCR rates and toxicity.